Literature DB >> 7896198

Vulvar intraepithelial neoplasia III: a viral disease of undetermined progressive potential.

U Hørding1, J Junge, H Poulsen, F Lundvall.   

Abstract

Seventy-three patients with vulvar intraepithelial neoplasia (VIN) grade III were followed for a median of 5 years after primary treatment. Thirty women also had a diagnosis of cervical neoplasia. During the follow-up 26 patients (36%) had one or more vulvar recurrences. Recurrences were seen significantly more often in the patients who also had cervical neoplasia, indicating a common etiology. Microinvasive carcinoma developed in 12 patients, 3 of whom later developed frankly invasive vulvar cancer. The original, paraffin-embedded vulvar specimens were examined by the polymerase chain reaction for human papillomavirus DNA of the types HPV 6, 11, 16, 18, and 33. HPV types 16 and 33 were found in 90% of the VIN lesions. It is concluded that VIN III is an HPV-related disease in all or almost all cases, and that a generalized genital HPV infection may be a factor in the development of multicentric genital neoplasia. No association was observed between the specific HPV type and the risk of recurrent vulvar disease, cervical neoplasia, or malignant progression.

Entities:  

Mesh:

Year:  1995        PMID: 7896198     DOI: 10.1006/gyno.1995.1046

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  9 in total

1.  [Cervix carcinoma--Austrian Vaccination Committee recommends HPV vaccination].

Authors:  Lucia Six; Elmar A Joura
Journal:  Wien Med Wochenschr       Date:  2007

2.  Comprehensive analysis of 130 multicentric intraepithelial female lower genital tract lesions by HPV typing and p16 expression profile.

Authors:  Monika Hampl; Nicolas Wentzensen; Svetlana Vinokurova; Magnus von Knebel-Doeberitz; Cristopher Poremba; Hans G Bender; Volkmar Kueppers
Journal:  J Cancer Res Clin Oncol       Date:  2006-11-25       Impact factor: 4.553

3.  Vulval Intraepithelial Neoplasia 3: A Clinico-Pathological Review in a Tertiary Care Centre Over 10 Years.

Authors:  Karthik C Bassetty; Anitha Thomas; Rachel G Chandy; Dhanya S Thomas; Vinotha Thomas; Abraham Peedicayil; Ajit Sebastian
Journal:  J Obstet Gynaecol India       Date:  2022-04-06

4.  Vulvar Intraepithelial Neoplasia 3 in Women Less Than 35 Years.

Authors:  Joshua P Kesterson; Shashikant Lele
Journal:  J Low Genit Tract Dis       Date:  2009-10       Impact factor: 1.925

5.  An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression.

Authors:  A E Rice; Y E Latchman; J P Balint; J H Lee; E S Gabitzsch; F R Jones
Journal:  Cancer Gene Ther       Date:  2015-09-04       Impact factor: 5.987

6.  Vulvar intraepithelial neoplasia (VIN 2/3): comparing clinical outcomes and evaluating risk factors for recurrence.

Authors:  J J Wallbillich; H E Rhodes; A M Milbourne; M F Munsell; M Frumovitz; J Brown; C L Trimble; K M Schmeler
Journal:  Gynecol Oncol       Date:  2012-08-04       Impact factor: 5.482

Review 7.  Squamous precursor lesions of the vulva: current classification and diagnostic challenges.

Authors:  Lien N Hoang; Kay J Park; Robert A Soslow; Rajmohan Murali
Journal:  Pathology       Date:  2016-04-23       Impact factor: 5.306

8.  Economic burden of vulvar and vaginal intraepithelial neoplasia: retrospective cost study at a German dysplasia centre.

Authors:  Monika Hampl; Eduard Huppertz; Olaf Schulz-Holstege; Patrick Kok; Sarah Schmitter
Journal:  BMC Infect Dis       Date:  2011-03-22       Impact factor: 3.090

9.  Immunohistochemical analysis of p53 in vulval intraepithelial neoplasia and vulval squamous cell carcinoma.

Authors:  A N Rosenthal; D Hopster; A Ryan; I J Jacobs
Journal:  Br J Cancer       Date:  2003-01-27       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.